KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Accured Expenses: 2009-2025

Historic Change in Accured Expenses for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Sep 2025 value amounting to $113.9 million.

  • Biomarin Pharmaceutical's Change in Accured Expenses fell 6.82% to $113.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.2 million, marking a year-over-year decrease of 76.14%. This contributed to the annual value of -$32.2 million for FY2024, which is 146.82% down from last year.
  • Biomarin Pharmaceutical's Change in Accured Expenses amounted to $113.9 million in Q3 2025, which was up 1,290.88% from $8.2 million recorded in Q2 2025.
  • Biomarin Pharmaceutical's 5-year Change in Accured Expenses high stood at $122.3 million for Q3 2024, and its period low was -$100.3 million during Q4 2024.
  • Its 3-year average for Change in Accured Expenses is $14.2 million, with a median of $6.6 million in 2023.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Change in Accured Expenses skyrocketed by 3,607.79% in 2021, and later crashed by 900.79% in 2024.
  • Over the past 5 years, Biomarin Pharmaceutical's Change in Accured Expenses (Quarterly) stood at $22.8 million in 2021, then spiked by 172.90% to $62.3 million in 2022, then slumped by 79.89% to $12.5 million in 2023, then tumbled by 900.79% to -$100.3 million in 2024, then fell by 6.82% to $113.9 million in 2025.
  • Its Change in Accured Expenses stands at $113.9 million for Q3 2025, versus $8.2 million for Q2 2025 and -$2.7 million for Q1 2025.